Curant Rare Partners as Exclusive Pharmacy for FDA-Approved Neuroblastoma Drug IWILFIN™

Curant Rare Becomes Exclusive Pharmacy Partner for IWILFIN™, Transforming Access and Care for High-Risk Neuroblastoma Patients Curant Health has announced a major milestone in oncology care through its specialty division, Curant Rare, which is now the exclusive pharmacy partner for…

Read MoreCurant Rare Partners as Exclusive Pharmacy for FDA-Approved Neuroblastoma Drug IWILFIN™

Dental Soft Tissue Regeneration Market 2025–2031 | Key Players & Competitive Outlook

Global Dental Soft Tissue Regeneration Market Report 2025–2031 The global dental soft tissue regeneration market has entered a phase of accelerated expansion, shaped by growing clinical demand, evolving patient expectations, and a wave of technological innovations. According to recent market…

Read MoreDental Soft Tissue Regeneration Market 2025–2031 | Key Players & Competitive Outlook